Preview

Экспериментальная и клиническая гастроэнтерология

Расширенный поиск

Диареи у взрослых. Клинические рекомендации. Проект

https://doi.org/10.31146/1682-8658-ecg-178-6-4-41

Полный текст:

Об авторах

А. С. Сарсенбаева
ФГБОУ ВО ЮУГМУ Минздрава России
Россия

кафедра терапии ИДПО, профессор, доктор медицинских наук,

454092, Уральский федеральный округ, Челябинская область, г. Челябинск, ул. Воровского, 64



Л. Б. Лазебник
Московский государственный медико-стоматологический университет им. АИ Евдокимова
Россия

кафедра Поликлинической терапии, профессор, доктор медицинских наук,

Москва, ул Вучетича 9а стр 1



Список литературы

1. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Can Med Assoc J 2010;182: E839–E842. 10.1503/cmaj.090449.

2. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383–94. 10.1016/j.jclinepi.2010.04.026.

3. Oxford University. Centre for evidence-based medicine. Oxford: Oxford University, 2009.

4. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology 2016;150:1393–407. 10.1053/j.gastro.2016.02.031.

5. Wenzl HH, Fine KD, Schiller LR, et al. Determinants of decreased fecal consistency in patients with diarrhea. Gastroenterology 1995;108:1729–38. 10.1016/0016-5085(95)90134-5.

6. O’Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990;300:439–40. 10.1136/bmj.300.6722.439.

7. Madoff RD, Williams JG, Caushaj PF. Fecal incontinence. N Engl J Med 1992;326:1002-7.10.1056/NEJM199204093261507.

8. Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999;116:1464–86. 10.1016/S0016-5085(99)70513-5.

9. Stotzer P-O, Abrahamsson H, Bajor A, et al. Are the definitions for chronic diarrhoea adequate? Evaluation of two different definitions in patients with chronic diarrhoea. United Eur Gastroenterol J 2015;3:381–6. 10.1177/2050640615580219.

10. Talley NJ, Weaver AL, Zinsmeister AR, et al. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992;136:165–77. 10.1093/oxfordjournals.aje.a116483.

11. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. BMJ 1978;2:653-4.10.1136/bmj.2.6138.653.

12. Sood R, Camilleri M, Gracie DJ, et al. Enhancing diagnostic performance of symptom-based criteria for irritable bowel syndrome by additional history and limited diagnostic evaluation. Am J Gastroenterol 2016;111:1446-54.10.1038/ajg.2016.308.

13. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014;6:71-80.10.2147/CLEP.S40245.

14. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712–21. 10.1016/j.cgh.2012.02.029.

15. Duncan A, Hill PG. A UK survey of laboratory-based gastrointestinal investigations. Ann Clin Biochem 1998;35(Pt 4):492–503. 10.1177/000456329803500403.

16. Jones R. Primary care research and clinical practice: gastroenterology. Postgrad Med J 2008;84:454-8.10.1136/pgmj.2008.068361.

17. Schiller LR, Pardi DS, Spiller R, et al. Gastro 2013 APDW/ WCOG Shanghai Working Party Report: Chronic diarrhea: Definition, classifi cation, diagnosis. J Gastroenterol Hepatol 2014;29:6–25. 10.1111/jgh.12392.

18. Whitehead WE, Palsson OS, Simrén M. Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management? Expert Rev Gastroenterol Hepatol 2017;11:281–3. 10.1080/17474124.2017.1292130.

19. Talley NJ, Phillips SF, Melton LJ, et al. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut 1990;31:77–81. 10.1136/gut.31.1.77.

20. Thompson WG. Gastrointestinal symptoms in the irritable bowel compared with peptic ulcer and inflammatory bowel disease. Gut 1984;25:1089–92. 10.1136/gut.25.10.1089.

21. Arrambide KA, Santa Ana CA, Schiller LR, et al. Loss of absorptive capacity for sodium chloride as a cause of diarrhea following partial ileal and right colon resection. Dig Dis Sci 1989;34:193–201. 10.1007/BF01536050.

22. Ros E, Zambon D. Postcholecystectomy symptoms. A prospective study of gall stone patients before and two years after surgery. Gut 1987;28:1500–4. 10.1136/gut.28.11.1500.

23. Valdovinos MA, Camilleri M, Zimmerman BR. Chronic diarrhea in diabetes mellitus: mechanisms and an approach to diagnosis and treatment. Mayo Clin Proc 1993;68:691–702. 10.1016/S0025-6196(12)60606-5.

24. Person J. Alcohol and the small intestine. Scand J Gastroenterol 1991;26:3–15. 10.3109/00365529108996478.

25. Jain NK, Rosenberg DB, Ulahannan MJ, et al. Sorbitol intolerance in adults. Am J Gastroenterol 1985;80:678–81.

26. Read NW, Krejs GJ, Read MG, et al. Chronic diarrhea of unknown origin. Gastroenterology 1980;78:264–71.

27. Ackerman Z, Eliakim R, Stalnikowicz R, et al. Role of small bowel biopsy in the endoscopic evaluation of adults with iron deficiency anemia. Am J Gastroenterol 1996;91:2099–102.

28. Goddard AF, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. British Society of Gastroenterology. Gut 2000;46(Suppl 3–4): IV1–IV5.

29. American Gastroenterological Association. Medical position statement: celiac sprue. Gastroenterology 2001;120:1522–5.

30. West J, et al. Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut 2003;52:960–5. 10.1136/gut.52.7.960.

31. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States. Arch Intern Med 2003;163:286–92. 10.1001/archinte.163.3.286.

32. Green PH, Jabri B. Coeliac disease. Lancet 2003;362:383– 91. 10.1016/S0140-6736(03)14027-5.

33. Catassi C, Kryszak D, Bhatti B, et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med 2010;42:530–8. 10.3109/07853890.2010.514285.

34. Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Th er 2007;26:1217–25. 10.1111/j.1365-2036.2007.03502.x.

35. Rubio–Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009;137:88–93. 10.1053/j.gastro.2009.03.059.

36. Green PHR. Th e many faces of celiac disease: Clinical presentation of celiac disease in the adult population. Gastroenterology 2005;128(4): S74–S78. 10.1053/j.gastro.2005.02.016.

37. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: An evolving spectrum. Gastroenterology 2001;120:636–51. 10.1053/gast.2001.22123.

38. Hopper AD, Hadjivassiliou M, Butt S, et al. Adult coeliac disease. BMJ 2007;335:558–62. 10.1136/bmj.39316.442338.AD.

39. Ferguson A, Arranz E, O’Mahony S. Clinical and pathological spectrum of coeliac disease–active, silent, latent, potential. Gut 1993;34:150–1. 10.1136/gut.34.2.150.

40. Sanders DS, Carter MJ, Hurlstone DP, et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001;358:1504–8. 10.1016/S0140-6736(01)06581-3.

41. Sanders DS, et al. Changing face of adult coeliac disease: experience of a single university hospital in South Yorkshire. Postgrad Med J 2002;78:31–3. 10.1136/pmj.78.915.31.

42. Green PHR, Stavropoulos SN, Panagi SG, et al. Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol 2001;96:126–31. 10.1111/j.1572-0241.2001.03462.x.

43. Richey R, Howdle P, Shaw E, et al. [Recognition and assessment of celiac disease in children and adults: summary of NICE guideline]. Praxis 2009;98:1233–5. 10.1024/1661-8157.98.21.1233.

44. Cranney A, Zarkadas M, Graham ID, et al. Th e Canadian Celiac Health Survey. Dig Dis Sci 2007;52:1087–95. 10.1007/s10620-006-9258-2.

45. Lo W, Sano K, Lebwohl B, et al. Changing presentation of adult celiac disease. Dig Dis Sci 2003;48:395–8. 10.1023/A:1021956200382.

46. Fernández-Bañares F, Esteve M, Salas A, et al. Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics. Am J Gastroenterol 2007;102:2520–8. 10.1111/j.1572-0241.2007.01438.x.

47. Hopper AD, Cross SS, Hurlstone DP, et al. Pre-endoscopy serological testing for coeliac disease: evaluation of a clinical decision tool. BMJ 2007;334:729 10.1136/bmj.39133.668681.BE.

48. Hill ID. What are the sensitivity and specifi city of serologic tests for celiac disease? Do sensitivity and specifi city vary in different populations? Gastroenterology 2005;128(4): S25–S32. 10.1053/j.gastro.2005.02.012.

49. Tursi A, Giorgetti G, Brandimarte G, et al. Prevalence and clinical presentation of subclinical/silent celiac disease in adults: an analysis on a 12-year observation. Hepatogastroenterology 2001;48:462–4.

50. Collin P, Kaukinen K, Vogelsang H, et al. Antiendomysial and antihuman recombinant tissue transglutaminase antibodies in the diagnosis of coeliac disease: a biopsy-proven European multicentre study. Eur J Gastroenterol Hepatol 2005;17:85–91.

51. Rostami K, Kerckhaert J, Tiemessen R, et al. Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice. Am J Gastroenterol 1999;94:888–94. 10.1111/j.1572-0241.1999.983_f.x.

52. Tursi A, Brandimarte G, Giorgetti GM. Prevalence of antitissue transglutaminase antibodies in different degrees of intestinal damage in celiac disease. J Clin Gastroenterol 2003;36:219–21. 10.1097/00004836-200303000-00007.

53. Harrison E, Li K-K, Petchey M, et al. Selective measurement of anti-tTG antibodies in coeliac disease and IgA deficiency: an alternative pathway. Postgrad Med J 2013;89:4–7. 10.1136/postgradmedj-2011-130188.

54. Elfstrand L, Florén CH. Management of chronic diarrhea in HIV-infected patients: current treatment options, challenges and future directions. HIV/AIDS2010;2:219-24. 10.2147/HIV.S13191.

55. Isaac-Renton JL. Laboratory diagnosis of giardiasis. Clin Lab Med 1991;11:811–27.

56. Rosenblatt JE, Sloan LM, Schneider SK. Evaluation of an enzyme-linked immunosorbent assay for the detection of Giardia lamblia in stool specimens. Diagn Microbiol Infect Dis 1993;16:337–41. 10.1016/0732-8893(93)90086-M.

57. Mank TG, Zaat JOM, Deelder AM, et al. Sensitivity of microscopy versus enzyme immunoassay in the laboratory diagnosis of giardiasis. Eur J Clin Microbiol Infect Dis 1997;16:615–9. 10.1007/BF02447929.

58. Zaat JOM, Mank TG, Assendelft WJJ. A systematic review on the treatment of giardiasis. Trop Med Int Health 1997;2:63–82. 10.1046/j.1365-3156.1997.d01-132.x.

59. Dhanalakshmi S, Meenachi C, Parija SC. Indirect haemagglutination test in comparison with ELISA for detection of antibodies against invasive amoebiasis. J Clin Diagn Res 2016;10: DC05–8. 10.7860/JCDR/2016/21566.8326.

60. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281–9. 10.1016/S1473–3099(11)70374–7.

61. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med Overseas Ed 2011;364:422–31. 10.1056/NEJMoa0910812.

62. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med Overseas Ed 2017;376:305–17. 10.1056/NEJMoa1602615.

63. Davies KA, Longshaw CM, Davis GL, et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 2014;14:1208–19. 10.1016/S1473-3099(14)70991-0.

64. Wadhwa A, Al Nahhas MF, Dierkhising RA, et al. High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection. Aliment Pharmacol Th er 2016;44:576–82. 10.1111/apt.13737.

65. Schiller LR, Pardi DS, Sellin JH. Chronic diarrhea: diagnosis and management. Clin Gastroenterol Hepatol 2017;15:182–93. 10.1016/j.cgh.2016.07.028.

66. Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess 2013;17: xv–xix. 10.3310/hta17550.

67. Dhaliwal A, Zeino Z, Tomkins C, et al. Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-off s should we apply? Frontline Gastroenterol 2015;6:14–19. 10.1136/flgastro-2013-100420.

68. McFarlane M, Chambers S, Dhaliwal A, et al. Is NICE too optimistic about savings from faecal calprotectin testing? Value Health 2015;18: A623 10.1016/j.jval.2015.09.2189.

69. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362–6. 10.1136/gut.45.3.362.

70. Kawashima K, Ishihara S, Yuki T, et al. Fecal calprotectin more accurately predicts endoscopic remission of Crohn's disease than serological biomarkers evaluated using balloon-assisted enteroscopy. Inflamm Bowel Dis 2017;23:2027–34. 10.1097/MIB.0000000000001202.

71. McFarlane M, Chambers S, Malik A, et al. Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a ‘real-world’ view. BMJ Open 2016;6: e011041 10.1136/bmjopen-2016-011041.

72. Karsa Lv, Lignini TA, Patnick J, et al. Th e dimensions of the CRC problem. Best Pract Res Clin Gastroenterol 2010;24:381–96. 10.1016/j.bpg.2010.06.004.

73. Mowat C, Digby J, Strachan JA, et al. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms. Gut 2016;65:1463–9. 10.1136/gutjnl-2015-309579.

74. Quyn AJ, Steele RJ, Digby J, et al. Application of NICE guideline NG12 to the initial assessment of patients with lower gastrointestinal symptoms: not FIT for purpose? Ann Clin Biochem 2018;55:69–76. 10.1177/0004563217707981.

75. Widlak MM, Thomas CL, Thomas MG, et al. Diagnostic accuracy of faecal biomarkers in detecting colorectal cancer and adenoma in symptomatic patients. Aliment Pharmacol Ther 2017;45:354–63. 10.1111/apt.13865.

76. Dalrymple J, Bullock I. Diagnosis and management of irritable bowel syndrome in adults in primary care: summary of NICE guidance. BMJ 2008;336:556–8. 10.1136/bmj.39484.712616.AD.

77. Rezaie A, Park SC, Morales W, et al. Assessment of anti-vinculin and anti-cytolethal distending toxin B antibodies in subtypes of irritable bowel syndrome. Dig Dis Sci 2017;62:1480-5. 10.1007/s10620-017-4585-z.

78. Neugut AI, Garbowski GC, Waye JD, et al. Diagnostic yield of colorectal neoplasia with colonoscopy for abdominal pain, change in bowel habits, and rectal bleeding. Am J Gastroenterol 1993;88:1179–83.

79. Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000;343:162–8. 10.1056/NEJM200007203430301.

80. Marshall JB, Singh R, Diaz-Arias AA. Chronic, unexplained diarrhea: are biopsies necessary if colonoscopy is normal? Am J Gastroenterol 1995;90:372–6.

81. Shah RJ, Fenoglio-Preiser C, Bleau BL, et al. Usefulness of colonoscopy with biopsy in the evaluation of patients with chronic diarrhea. Am J Gastroenterol 2001;96:1091– 5. 10.1111/j.1572-0241.2001.03745.x.

82. Shale MJH, Walters JRF, Westaby D. Adequacy of flexible sigmoidoscopy with biopsy for diarrhea in patients under age 50 without features of proximal disease. Gastrointest Endosc 2011;73:757–64. 10.1016/j.gie.2010.11.037.

83. Tanaka M, Mazzoleni G, Riddell RH. Distribution of collagenous colitis: utility of flexible sigmoidoscopy. Gut 1992;33:65–70. 10.1136/gut.33.1.65.

84. Zwas FR, Bonheim NA, Berken CA, et al. Diagnostic yield of routine ileoscopy. Am J Gastroenterol 1995;90:1441–3.

85. Geboes K, Ectors N, D’Haens G, et al. Is ileoscopy with biopsy worthwhile in patients presenting with symptoms of inflammatory bowel disease? Am J Gastroenterol 1998;93:201–6. 10.1111/j.1572-0241.1998.00201.x.

86. Winawer SJ, Stewart ET, Zauber AG, et al. A comparison of colonoscopy and double-contrast barium enema for surveillance aft er polypectomy. N Engl J Med Overseas Ed 2000;342:1766–72. 10.1056/NEJM200006153422401.

87. Arasaradnam RP, Cullis J, Nwokolo C, et al. Bile acid malabsorption and SeHCAT: the ’Cinderella’ will be going to the Nuclear Medicine Ball!. Nucl Med Commun 2012;33:449–51. 10.1097/MNM.0b013e328351d516.

88. Fine KD, Seidel RH, Do K. Th e prevalence, anatomic distribution, and diagnosis of colonic causes of chronic diarrhea. Gastrointest Endosc 2000;51:318–26. 10.1016/ S0016-5107(00)70362-2.

89. Paulsen SR, Huprich JE, Fletcher JG, et al. CT enterography as a diagnostic tool in evaluating small bowel disorders: review of clinical experience with over 700 cases. Radiographics 2006;26:641–57. 10.1148/rg.263055162.

90. Castiglione F, Mainenti PP, De Palma GD, et al. Noninvasive diagnosis of small bowel Crohn’s disease: direct comparison of bowel sonography and magnetic resonance enterography. Inflamm Bowel Dis 2013;19:991–8. 10.1097/MIB.0b013e3182802b87.

91. Fraquelli M, Colli A, Casazza G, et al. Role of US in detection of Crohn disease: meta-analysis. Radiology 2005;236:95–101. 10.1148/radiol.2361040799.

92. Panés J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther 2011;34:125– 45. 10.1111/j.1365-2036.2011.04710.x.

93. Gourtsoyiannis N, Papanikolaou N, Grammatikakis J, et al. MR enteroclysis: technical considerations and clinical applications. Eur Radiol 2002;12:2651–8. 10.1007/s00330-002-1507-y.

94. Gourtsoyiannis NC, Grammatikakis J, Papamastorakis G, et al. Imaging of small intestinal Crohn’s disease: comparison between MR enteroclysis and conventional enteroclysis. Eur Radiol 2006;16:1915–25. 10.1007/s00330-006-0248-8.

95. Rajesh A, Maglinte DDT. Multislice CT enteroclysis: technique and clinical applications. Clin Radiol 2006;61:31–9. 10.1016/j.crad.2005.08.006.

96. Negaard A, Paulsen V, Sandvik L, et al. A prospective randomized comparison between two MRI studies of the small bowel in Crohn’s disease, the oral contrast method and MR enteroclysis. Eur Radiol 2007;17:2294–301. 10.1007/s00330–007–0648–4.

97. Negaard A, Sandvik L, Berstad AE, et al. MRI of the small bowel with oral contrast or nasojejunal intubation in Crohn’s disease: randomized comparison of patient acceptance. Scand J Gastroenterol 2008;43:44–51. 10.1080/00365520701494813.

98. Horsthuis K, Bipat S, Bennink RJ, et al. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology 2008;247:64–79. 10.1148/radiol.2471070611.

99. Horsthuis K, Stokkers PCF, Stoker J. Detection of inflammatory bowel disease: diagnostic performance of cross-sectional imaging modalities. Abdom Imaging 2008;33:407–16. 10.1007/s00261-007-9276-3.

100. Ryan ER, Heaslip ISE. Magnetic resonance enteroclysis compared with conventional enteroclysis and computed tomography enteroclysis: a critically appraised topic. Abdom Imaging 2008;33:34–7. 10.1007/s00261-007-9308-z.

101. Sinha R, Murphy P, Sanders S, et al. Diagnostic accuracy of high-resolution MR enterography in Crohn’s disease: comparison with surgical and pathological specimen. Clin Radiol 2013;68:917–27. 10.1016/j.crad.2013.02.012.

102. Oussalah A, Laurent V, Bruot O, et al. Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut 2010;59:1056–65. 10.1136/gut.2009.197665.

103. Sinha R, Rajiah P, Ramachandran I, et al. Diffusion weighted MR imaging of the gastrointestinal tract: technique, indications, and imaging findings. Radiographics 2013;33:655–76. 10.1148/rg.333125042.

104. Desmond AN, O’Regan K, Curran C, et al. Crohn’s disease: factors associated with exposure to high levels of diagnostic radiation. Gut 2008;57:1524–9. 10.1136/gut.2008.151415.

105. Masselli G, Di Tola M, Casciani E, et al. Diagnosis of small-bowel diseases: prospective comparison of multidetector row CT enterography with MR enterography. Radiology 2016;279:420–31. 10.1148/radiol.2015150263.

106. Pennazio M, Spada C, Eliakim R, et al. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. Endoscopy 2015;47:352–86. 10.1055/s-0034-1391855.

107. Landi B, Tkoub M, Gaudric M, et al. Diagnostic yield of push-type enteroscopy in relation to indication. Gut 1998;42:421–5. 10.1136/gut.42.3.421.

108. Sidhu R, Sanders DS, Morris AJ, et al. Guidelines on small bowel enteroscopy and capsule endoscopy in adults. Gut 2008;57:125–36. 10.1136/gut.2007.129999.

109. Smith MJ, Cherian P, Raju GS, et al. Bile acid malabsorption in persistent diarrhoea. J R Coll Physicians Lond 2000;34:448–5.

110. Bannaga A, Kelman L, O’Connor M, et al. How bad is bile acid diarrhoea: an online survey of patient-reported symptoms and outcomes. BMJ Open Gastroenterol 2017;4: e000116 10.1136/bmjgast-2016-000116.

111. Walters JR. Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol 2014;11:426–34. 10.1038/nrgastro.2014.32.

112. Walters JRF. Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder. Expert Rev Gastroenterol Hepatol 2010;4:561–7. 10.1586/egh.10.54.

113. Merrick MV, Eastwood MA, Anderson JR, et al. Entero hepatic circulation in man of a gamma-emitting bile-acid conjugate, 23-selena-25-homotaurocholic acid (SeHCAT). J Nucl Med 1982;23:126–30.

114. Merrick MV, Eastwood MA, Ford MJ. Is bile acid malabsorption underdiagnosed? An evaluation of accuracy of diagnosis by measurement of SeHCAT retention. BMJ 1985;290:665–8. 10.1136/bmj.290.6469.665.

115. Wedlake L, A’HERN R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Th er 2009;30:707–17. 10.1111/j.1365-2036.2009.04081.x.

116. Ross S, D’Mello M, Anand SS, et al. Effect of bile acid sequestrants on the risk of cardiovascular events: a mendelian randomization analysis. Circ Cardiovasc Genet 2015;8:618–27. 10.1161/CIRCGENETICS.114.000952.

117. Sauter GH, Münzing W, von Ritter C, et al. Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum. Dig Dis Sci 1999;44:14–19. 10.1023/A:1026681512303.

118. Camilleri M. Advances in understanding of bile acid diarrhea. Expert Rev Gastroenterol Hepatol 2014;8:49–61. 10.1586/17474124.2014.851599.

119. Camilleri M, Busciglio I, Acosta A, et al. Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea. Am J Gastroenterol 2014;109:1621–30. 10.1038/ajg.2014.215.

120. Covington J, Westenbrink E, Ouaret N, et al. Application of a novel tool for diagnosing bile acid diarrhoea. Sensors 2013;13:11899–912. 10.3390/s130911899.

121. Camilleri M. Bile acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver 2015;9:332–9. 10.5009/gnl14397.

122. Valentin N, Camilleri M, Altayar O, et al. Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis. Gut 2016;65:1951–9. 10.1136/gutjnl-2015-309889.

123. Kurien M, Evans KE, Leeds JS, et al. Bile acid malabsorption: an under-investigated differential diagnosis in patients presenting with diarrhea predominant irritable bowel syndrome type symptoms. Scand J Gastroenterol 2011;46(7–8):818–22. 10.3109/00365521.2011.574728.

124. Bajor A, Törnblom H, Rudling M, et al. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut 2015;64:84–92. 10.1136/gutjnl-2013-305965.

125. Nyhlin H, Merrick MV, Eastwood MA. Bile acid malabsorption in Crohn’s disease and indications for its assessment using SeHCAT. Gut 1994;35:90–3. 10.1136/gut.35.1.90.

126. Sciarretta G, Furno A, Mazzoni M, et al. Post-cholecystectomy diarrhea: evidence of bile acid malabsorption assessed by SeHCAT test. Am J Gastroenterol 1992;87:1852–4.

127. Fernández-Bañares F, Esteve M, Salas A, et al. Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea. Dig Dis Sci 2001;46:2231–8. 10.1023/A:1011927302076.

128. Phillips F, Muls ACG, Lalji A, et al. Are bile acid malabsorption and bile acid diarrhoea important causes of loose stool complicating cancer therapy? Colorectal Dis 2015;17:730–4. 10.1111/codi.12932.

129. Riemsma R, Al M, Corro Ramos I, et al. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis. Health Technol Assess 2013;17:1–236. 10.3310/hta17610.

130. Kurien M, Th urgar E, Davies A, et al. Challenging current views on bile acid diarrhoea and malabsorption. Frontline Gastroenterol 2017: flgastro-2017–100808 10.1136/flgastro-2017–100808.

131. Turner JM, Pattni SS, Appleby RN, et al. A positive SeHCAT test results in fewer subsequent investigations in patients with chronic diarrhoea. Frontline Gastroenterol 2017;8:279–83. 10.1136/flgastro-2017-100826.

132. Orekoya O, McLaughlin J, Leitao E, et al. Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy. Clin Med 2015;15:252–7. 10.7861/clinmedicine.15-3-252.

133. Münch A, Aust D, Bohr J, et al. Microscopic colitis: current status, present and future challenges: statements of the European Microscopic Colitis Group. J Crohns Colitis 2012;6:932–45. 10.1016/j.crohns.2012.05.014.

134. Bogomoletz WV, Adnet JJ, Birembaut P, et al. Collagenous colitis: an unrecognised entity. Gut 1980;21:164–8. 10.1136/gut.21.2.164.

135. Kingham JG, Levison DA, Ball JA, et al. Microscopic colitis: a cause of chronic watery diarrhoea. BMJ 1982;285:1601–4. 10.1136/bmj.285.6355.1601.

136. Langner C, Aust D, Ensari A, et al. Histology of microscopic colitis-review with a practical approach for pathologists. Histopathology 2015;66:613–26. 10.1111/his.12592.

137. Pardi DS, Kelly CP. Microscopic colitis. Gastroenterology 2011;140:1155–65. 10.1053/j.gastro.2011.02.003.

138. Rasmussen MA, Munck LK. Systematic review: are lymphocytic colitis and collagenous colitis two subtypes of the same disease–microscopic colitis? Aliment Pharmacol Ther 2012;36:79–90. 10.1111/j.1365-2036.2012.05166.x.

139. Tong J, Zheng Q, Zhang C, et al. Incidence, prevalence, and temporal trends of microscopic colitis: a systematic review and meta-analysis. Am J Gastroenterol 2015;110:265–76. quiz 77 10.1038/ajg.2014.431.

140. Guagnozzi D, Arias Á, Lucendo AJ. Systematic review with meta-analysis: diagnostic overlap of microscopic colitis and functional bowel disorders. Aliment Pharmacol Th er 2016;43:851–62. 10.1111/apt.13573.

141. Kamp EJCA, Kane JS, Ford AC. Irritable bowel syndrome and microscopic colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:659–68. e1; quiz e54–5 10.1016/j.cgh.2015.09.031.

142. Nguyen GC, Smalley WE, Vege SS, et al. American Gastroenterological Association Institute guideline on the medical management of microscopic colitis. Gastroenterology 2016;150:242–6. quiz e17-8 10.1053/j.gastro.2015.11.008.

143. Pardi DS, Tremaine WJ, Carrasco-Labra A. American Gastroenterological Association Institute technical review on the medical management of microscopic colitis. Gastroenterology 2016;150:247–74. 10.1053/j.gastro.2015.11.006.

144. von Arnim U, Wex T, Ganzert C, et al. Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. Clin Exp Gastroenterol 2016;9:97–103. 10.2147/CEG.S97701.

145. Cotter TG, Binder M, Harper EP, et al. Optimization of a scoring system to predict microscopic colitis in a cohort of patients with chronic diarrhea. J Clin Gastroenterol 2017;51:228–34. 10.1097/MCG.0000000000000565.

146. Miehlke S, Madisch A, Bethke B, et al. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2008;135:1510–6. 10.1053/j.gastro.2008.07.081.

147. Münch A, Langner C. Microscopic colitis: clinical and pathologic perspectives. Clin Gastroenterol Hepatol 2015;13:228–36. 10.1016/j.cgh.2013.12.026.

148. Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. J Gastroenterol Hepatol 2010;25:252–8. 10.1111/j.1440-1746.2009.06149.x.

149. Major G, Pritchard S, Murray K, et al. Colon hypersensitivity to distension, rather than excessive gas production, produces carbohydrate-related symptoms in individuals with irritable bowel syndrome. Gastroenterology 2017;152:124–33. 10.1053/j.gastro.2016.09.062.

150. Shepherd SJ, Parker FC, Muir JG, et al. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 2008;6:765–71. 10.1016/j.cgh.2008.02.058.

151. Yang J, Deng Y, Chu H, et al. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013;11:262–8. 10.1016/j.cgh.2012.11.034.

152. Zhu Y, Zheng X, Cong Y, et al. Bloating and distention in irritable bowel syndrome: the role of gas production and visceral sensation after lactose ingestion in a population with lactase deficiency. Am J Gastroenterol 2013;108:1516–25. 10.1038/ajg.2013.198.

153. Jones HF, Butler RN, Brooks DA. Intestinal fructose transport and malabsorption in humans. Am J Physiol Gastrointest Liver Physiol 2011;300: G202–G206. 10.1152/ajpgi.00457.2010.

154. De Giorgio R, Volta U, Gibson PR, et al. Gluten and FODMAPs in IBS: facts or fiction? Gut 2016;65:169–78.

155. Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013;145:320–8. 10.1053/j.gastro.2013.04.051.

156. Deng Y, Misselwitz B, Dai N, et al. Lactose intolerance in adults: biological mechanism and dietary management. Nutrients 2015;7:8020–35. 10.3390/nu7095380.

157. Storhaug CL, Fosse SK, Fadnes LT. Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2017;2:738–46. 10.1016/S2468-1253(17)30154-1.

158. Zheng X, Chu H, Cong Y, et al. Self-reported lactose intolerance in clinic patients with functional gastrointestinal symptoms: prevalence, risk factors, and impact on food choices. Neurogastroenterol Motil 2015;27:1138–46. 10.1111/nmo.12602.

159. Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med Overseas Ed 1995;333:1–4. 10.1056/NEJM199507063330101.

160. Böhmer CJM, Tuynman HARE. The effect of a lactose-restricted diet in patients with a positive lactose tolerance test, earlier diagnosed as irritable bowel syndrome: a 5-year follow-up study. Eur J Gastroenterol Hepatol 2001;13:941–4. 10.1097/00042737-200108000-00011.

161. Corlew-Roath M, Di Palma JA. Clinical impact of identifying lactose maldigestion or fructose malabsorption in irritable bowel syndrome or other conditions. South Med J 2009;102:1010–2. 10.1097/SMJ.0b013e3181b64c7f.

162. Parker TJ, Woolner JT, Prevost AT, et al. Irritable bowel syndrome: is the search for lactose intolerance justified? Eur J Gastroenterol Hepatol 2001;13:219–25. 10.1097/00042737-200103000-00001.

163. Berg LK, Fagerli E, Martinussen M, et al. Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test. Scand J Gastroenterol 2013;48:936–43. 10.3109/00365521.2013.812139.

164. Halmos EP, Power VA, Shepherd SJ, et al. A diet low in fodmaps reduces symptoms of irritable bowel syndrome. Gastroenterology 2014;146:67–75. 10.1053/j.gastro.2013.09.046.

165. Melchior C, Gourcerol G, Déchelotte P, et al. Symptomatic fructose malabsorption in irritable bowel syndrome: a prospective study. United Eur Gastroenterol J 2014;2:131–7. 10.1177/2050640614521124.

166. Hauer-Jensen M, Denham JW, Andreyev HJN. Radiation enteropathy: pathogenesis, treatment and prevention. Nat Rev Gastroenterol Hepatol 2014;11:470–9. 10.1038/nrgastro.2014.46.

167. Dinning PG, Szczesniak MM, Cook IJ. Twenty-four hour spatiotemporal mapping of colonic propagating sequences provides pathophysiological insight into constipation. Neurogastroenterol Motil 2008;20:1017–21. 10.1111/j.1365-2982.2008.01147.x.

168. Lindberg G, Tornblom H, Iwarzon M, et al. Full-thickness biopsy findings in chronic intestinal pseudo-obstruction and enteric dysmotility. Gut 2009;58:1084–90. 10.1136/gut.2008.148296.

169. Posserud I, Stotzer P-O, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007;56:802–8. 10.1136/gut.2006.108712.

170. Soffer EE, Bruck R, Bar-Meir S. The role of short-term multilumen duodenojejunal manometry in patients with intestinal motor dysfunction. Gastroenterol Clin Biol 1988;12:123–5.

171. Stanghellini V, Cogliandro R, Cogliandro L, et al. Clinical use of manometry for the diagnosis of intestinal motor abnormalities. Dig Liver Dis 2000;32:532–41. 10.1016/S1590-8658(00)80011-0.

172. Marciani L, Cox EF, Hoad CL, et al. Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology 2010;138:469–77. 77 e1 10.1053/j.gastro.2009.10.055.

173. Fine KD, Fordtran JS. The effect of diarrhea on fecal fat excretion. Gastroenterology 1992;102:1936–9. 10.1016/0016-5085(92)90316-Q.

174. Th omas PD, Forbes A, Green J, et al. Guidelines for the investigation of chronic diarrhoea, 2nd edition. Gut 2003;52:1v-15. 10.1136/gut.52.suppl_5.v1.

175. Lankisch P, Dröge M, Hofses S, et al. Steatorrhoea: you cannot trust your eyes when it comes to diagnosis. Lancet 1996;347:1620–1. 10.1016/S0140-6736(96)91107-1.

176. Conwell DL, Lee LS, Yadav D, et al. American Pancreatic Association practice guidelines in chronic pancreatitis: evidence-based report on diagnostic guidelines. Pancreas 2014;43:1143–62. 10.1097/MPA.0000000000000237.

177. Frulloni L, Falconi M, Gabbrielli A, et al. Italian consensus guidelines for chronic pancreatitis. Dig Liver Dis 2010;42(Suppl 6): S381–S406. 10.1016/S1590-8658(10)60682-2.

178. Hoffmeister A, Mayerle J, Beglinger C, et al. English language version of the S3-consensus guidelines on chronic pancreatitis: definition, aetiology, diagnostic examinations, medical, endoscopic and surgical management of chronic pancreatitis. Z Gastroenterol 2015;53:1447–95. 10.1055/s-0041-107379.

179. Smith RC, Smith SF, Wilson J, et al. Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency. Pancreatology 2016;16:164–80. 10.1016/j.pan.2015.12.006.

180. Lankisch PG, Schmidt I, Konig H, et al. Faecal elastase 1: Not helpful in diagnosing chronic pancreatitis associated with mild to moderate exocrine pancreatic insuffi ciency. Gut 1998;42:551–4. 10.1136/gut.42.4.551.

181. Loser C, Mollgaard A, Folsch UR. Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut 1996;39:580–6. 10.1136/gut.39.4.580.

182. Sonwalkar SA, Holbrook IB, Phillips I, et al. A prospective, comparative study of the para-aminobenzoic acid test and faecal elastase 1 in the assessment of exocrine pancreatic function. Aliment Pharmacol Ther 2003;17:467–71. 10.1046/j.1365-2036.2003.01451.x.

183. Elphick DA, Kapur K. Comparing the urinary pancreolauryl ratio and faecal elastase-1 as indicators of pancreatic insufficiency in clinical practice. Pancreatology 2005;5(2–3):196–200. 10.1159/000085271.

184. Buscail L, Escourrou J, Moreau J, et al. Endoscopic ultrasonography in chronic pancreatitis: a comparative prospective study with conventional ultrasonography, computed tomography, and ERCP. Pancreas 1995;10:251–7.

185. Kusano S, Kaji T, Sugiura Y, et al. Ct demonstration of fi brous stroma in chronic pancreatitis: pathologic correlation. J Comput Assist Tomogr 1999;23:297–300. 10.1097/00004728-199903000-00022.

186. Arasaradnam RP, Wicaksono A, O’Brien H, et al. Noninvasive diagnosis of pancreatic cancer through detection of volatile organic compounds in urine. Gastroenterology 2018;154:485–7. 10.1053/j.gastro.2017.09.054.

187. Testoni PA, Mariani A, Curioni S, et al. Pancreatic ductal abnormalities documented by secretin-enhanced mrcp in asymptomatic subjects with chronic pancreatic hyperenzymemia. Am J Gastroenterol 2009;104:1780–6. 10.1038/ajg.2009.158.

188. Testoni PA, Mariani A, Curioni S, et al. MRCP-secretin test–guided management of idiopathic recurrent pancreatitis: long-term outcomes. Gastrointest Endosc 2008;67:1028–34. 10.1016/j.gie.2007.09.007.

189. Bian Y, et al. Quantification of pancreatic exocrine function of chronic pancreatitis with secretin-enhanced MRCP. World J Gastroenterol 2013;19:7177–82. 10.3748/wjg.v19.i41.7177.

190. Sanyal R, Stevens T, Novak E, et al. Secretin-enhanced MRCP: review of technique and application with proposal for quantification of exocrine function. AJR Am J Roentgenol 2012;198:124–32. 10.2214/AJR.10.5713.

191. Gillams A, Pereira S, Webster G, et al. Correlation of MRCP quantification (MRCPQ) with conventional non-invasive pancreatic exocrine function tests. Abdom Imaging 2008;33:469–73. 10.1007/s00261-007-9286-1.

192. Manfredi R, Perandini S, Mantovani W, et al. Quantitative MRCP assessment of pancreatic exocrine reserve and its correlation with faecal elastase-1 in patients with chronic pancreatitis. Radiol Med 2012;117:282–92. 10.1007/s11547-011-0774-6.

193. Trikudanathan G, Walker SP, Munigala S, et al. Diagnostic performance of contrast-enhanced MRI with secretin-stimulated MRCP for non-calcifi c chronic pancreatitis: a comparison with histopathology. Am J Gastroenterol 2015;110:1598–606. 10.1038/ajg.2015.297.

194. Seicean A. Endoscopic ultrasound in chronic pancreatitis: Where are we now? World J Gastroenterol 2010;16:4253–63. 10.3748/wjg.v16.i34.4253.

195. Stevens T, Conwell DL, Zuccaro G, et al. A prospective crossover study comparing secretin-stimulated endoscopic and Dreiling tube pancreatic function testing in patients evaluated for chronic pancreatitis. Gastrointest Endosc 2008;67:458–66. 10.1016/j.gie.2007.07.028.

196. Stevens T, Dumot JA, Parsi MA, et al. Combined endoscopic ultrasound and secretin endoscopic pancreatic function test in patients evaluated for chronic pancreatitis. Dig Dis Sci 2010;55:2681–7. 10.1007/s10620-009-1084-x.

197. Mariani A, Arcidiacono PG, Curioni S, et al. Diagnostic yield of ERCP and secretin-enhanced MRCP and EUS in patients with acute recurrent pancreatitis of unknown aetiology. Dig Liver Dis 2009;41:753–8. 10.1016/j.dld.2009.01.009.

198. Pungpapong S, Wallace MB, Woodward TA, et al. Accuracy of endoscopic ultrasonography and magnetic resonance cholangiopancreatography for the diagnosis of chronic pancreatitis. J Clin Gastroenterol 2007;41:88– 93. 10.1097/MCG.0b013e31802dfde6.

199. Go VL, Dimagno EP. Assessment of exocrine pancreatic function by duodenal intubation. Clin Gastroenterol 1984;13:701–15.

200. Lankisch PG. Function tests in the diagnosis of chronic pancreatitis. Critical evaluation. Int J Pancreatol 1993;14:9–20. 10.1007/BF02795225.

201. Axon AT, Classen M, Cotton PB, et al. Pancreatography in chronic pancreatitis: international definitions. Gut 1984;25:1107–12. 10.1136/gut.25.10.1107.

202. Valentini M, Cavallini G, Vantini I, et al. A comparative evaluation of endoscopic retrograde cholangiopancreatography and the secretin-cholecystokinin test in the diagnosis of chronic pancreatitis: a multicentre study in 124 patients. Endoscopy 1981;13:64–7. 10.1055/s-2007-1021649.

203. Niederau C, Grendell JH. Diagnosis of chronic pancreatitis. Gastroenterology 1985;88:1973–95. 10.1016/0016-5085(85)90029–0.

204. Keller J, Meier V, Wolfram KU, et al. Sensitivity and specificity of an abbreviated (13) C-mixed triglyceride breath test for measurement of pancreatic exocrine function. United Eur Gastroenterol J 2014;2:288–94. 10.1177/2050640614542496.

205. Choung RS, Ruff KC, Malhotra A, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Th er 2011;33:1059–67. 10.1111/j.1365-2036.2011.04625.x.

206. Browning GG, Buchan KA, Mackay C. The effect of vagotomy and drainage on the small bowel flora. Gut 1974;15:139–42. 10.1136/gut.15.2.139.

207. Brägelmann R, Armbrecht U, Rosemeyer D, et al. Small bowel bacterial overgrowth in patients after total gastrectomy. Eur J Clin Invest 1997;27:409–16. 10.1046/j.1365-2362.1997.1200674.x.

208. Lewis SJ, Potts LF, Malhotra R, et al. Small bowel bacterial overgrowth in subjects living in residential care homes. Age Ageing 1999;28:181–5. 10.1093/ageing/28.2.181.

209. Riordan SM, McIver CJ, Wakefi eld D, et al. Small intestinal bacterial overgrowth in the symptomatic elderly. Am J Gastroenterol 1997;92:47–51.

210. Saltzman JR, Kowdley KV, Pedrosa MC, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology 1994;106:615–23. 10.1016/0016-5085(94)90693-9.

211. Corazza GR, Menozzi MG, Strocchi A, et al. Th e diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology 1990;98:302–9.

212. Rhodes JM, Middleton P, Jewell DP. The lactulose hydrogen breath test as a diagnostic test for small-bowel bacterial overgrowth. Scand J Gastroenterol 1979;14:333–6. 10.3109/00365527909179892.

213. King CE, Toskes PP. Breath tests in the diagnosis of small intestine bacterial overgrowth. Crit Rev Clin Lab Sci 1984;21:269–81. 10.3109/10408368409165785.

214. Zhao J, Zheng X, Chu H, et al. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients. Neurogastroenterol Motil 2014;26:794–802. 10.1111/nmo.12331.

215. Th ompson DG, O’Brien JD, Hardie JM. Influence of the oropharyngeal microflora on the measurement of exhaled breath hydrogen. Gastroenterology 1986;91:853– 60. 10.1016/0016-5085(86)90686–4.

216. Saltzberg DM, Levine GM, Lubar C. Impact of age, sex, race, and functional complaints on hydrogen (H2) production. Dig Dis Sci 1988;33:308–13. 10.1007/BF01535755.

217. Erdogan A, Rao SS, Gulley D, et al. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil 2015;27:481–9. 10.1111/nmo.12516.

218. Riordan SM, McIver CJ, Walker BM, et al. The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol 1996;91:1795–803.

219. Lin EC, Massey BT. Scintigraphy demonstrates high rate of false-positive results from glucose breath tests for small bowel bacterial overgrowth. Clin Gastroenterol Hepatol 2016;14:203–8. 10.1016/j.cgh.2015.07.032.

220. Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011;60:334–40. 10.1136/gut.2009.205476.

221. Stotzer PO, Brandberg A, Kilander AF. Diagnosis of small intestinal bacterial overgrowth in clinical praxis: a comparison of the culture of small bowel aspirate, duodenal biopsies and gastric aspirate. Hepatogastroenterology 1998;45:1018–22.

222. Attar A, Flourié B, Rambaud JC, et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999;117:794–7. 10.1016/S0016-5085(99)70336-7.

223. Sanders DS, Hurlstone DP, Brown S. Does coeliac disease affect colorectal practice? Int J Colorectal Dis 2007;22:565–70. 10.1007/s00384-006-0234-2.

224. Cowlam S, Vinayagam R, Khan U, et al. Blinded comparison of faecal loading on plain radiography versus radio-opaque marker transit studies in the assessment of constipation. Clin Radiol 2008;63:1326–31. 10.1016/j.crad.2008.06.011.

225. Armbrecht U, Lundell L, Lindstedt G, et al. Causes of malabsorption after total gastrectomy with Roux-en-Y reconstruction. Acta Chir Scand 1988;154:37–41.

226. Swan RW. Stagnant loop syndrome resulting from small-bowel irradiation injury and intestinal by-pass. Gynecol Oncol 1974;2:441–5. 10.1016/0090-8258(74)-90052-3.

227. Castiglione F, Del Vecchio Blanco G, Rispo A, et al. Orocecal transit time and bacterial overgrowth in patients with Crohn’s disease. J Clin Gastroenterol 2000;31:63–6. 10.1097/00004836-200007000-00015.

228. Costi R, Randone B, Violi V, et al. Cholecystocolonic fistula: facts and myths. A review of the 231 published cases. J Hepatobiliary Pancreat Surg 2009;16:8–18. 10.1007/s00534-008-0014-1.

229. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol 2007;3:112–22.

230. Eriksson B, Oberg K, Skogseid B. Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients. Acta Oncol 1989;28:373–7. 10.3109/02841868909111209.

231. Reid MD, Balci S, Saka B, et al. Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr Pathol 2014;25:65–79. 10.1007/s12022-013-9295-2.

232. Mekhjian HS, O’Dorisio TM. VIPoma syndrome. Semin Oncol 1987;14:282–91.

233. Ganguli PC, Cullen DR, Irvine WJ. Radioimmunoassay of plasmagastrin in pernicious anaemia, achlorhydria without pernicious anaemia, hypochlorhydria, and in controls. Lancet 1971;1:155–8. 10.1016/S0140-6736(71)91932-5.

234. Caplin ME, Buscombe JR, Hilson AJ, et al. Carcinoid tumour. Lancet 1998;352:799–805. 10.1016/S0140-6736(98)02286-7.

235. Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012;61:6–32. 10.1136/gutjnl-2011-300831.

236. Eriksson B, Arnberg H, Lindgren PG, et al. Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med 1990;228:103–13. 10.1111/j.1365-2796.1990.tb00202.x.

237. Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 2017;18:525–34. 10.1016/S1470-2045(17)30110-9.

238. Afzalpurkar RG, Schiller LR, Little KH, et al. The self-limited nature of chronic idiopathic diarrhea. N Engl J Med 1992;327:1849–52. 10.1056/NEJM199212243272605.

239. Hungin AP, Paxman L, Koenig K, et al. Prevalence, symptom patterns and management of episodic diarrhoea in the community: a population-based survey in 11 countries. Aliment Pharmacol Ther 2016;43:586–95. 10.1111/apt.13513

240. Arasaradnam RP, Brown S, Forbes A, et al. Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. Gut 2018;67:1380-1399. doi:10.1136/gutjnl-2017-315909

241. Парфенов А. И. Энтерология. Руководство для врачей. Москва, «Триада-Х», 2002, 744 c. Parfenov A. I. Enterology. Manual for doctors. Moscow. “Triada-X”, 2002, 744 p.

242. Парфенов А. И. Энтерология. 2-е издание. Издательство: Медицинское информационное агентство. 2009. – 875 с. Parfenov A. I. Enterology. 2nd edition. Medical Information agency Publ. 2009. 875 p.

243. Медицинский журнал «Медицинские анализы врачам-гастроэнтерологам», 2018 г. 30 с. Medical journal “Medical tests for gastroenterologists”, 2018. 30 p.

244. Кузнецов В. И. Клиническая фармакология. Учебник 2-e издание перераб и доп. 2015 г. Kuznetsov V. I. Clinical Pharmacology. Textbook 2nd Edition revised and ext. 2015.

245. Клинические рекомендации Кишечная стома у взрослых. КР 181,2016

246. Клинические рекомендации Рак ободочной кишки и сигмовидной кишки КР 39, 2016

247. Клинические рекомендации Целиакия у детей КР 404. 2016

248. Клинические рекомендации Рак прямой кишки КР 554. 2016

249. Клинические рекомендации Шигеллез у взрослых КР 498, 2016

250. Клинические рекомендации РГА по ведению больных с Болезнью Крона, 2016

251. Клинические рекомендации Амебиаз у детей, КР 556. 2016

252. Клинические рекомендации (протокол) по оказанию скорой медицинской помощи при синдроме диареи инфекционного генеза (Национальные клинические рекомендации) (Общероссийская общественная организация «Российское общество скорой медицинской помощи», 2014. Lioznov D. A., Karnaukhova E. Yu., et al. Clinical recommendations (protocol) for the provision of emergency medical care in case of diarrhea syndrome of infectious origin. (January 23, 2014 in Kazan / Russian Society for Emergency Medicine, (National Clinical Recommendations), 2014.

253. Боль в животе. Клинические рекомендации. Общероссийская общественная организация «Ассоциация врачей общей практики (семейных врачей) Российской Федерации. Москва-Санкт Петербург-Ростов на Дону, 2014

254. Выявление уровня кальпротектина в копрофильтратах для дифференциальной диагностики и мониторирования эффективности лечения больных с воспалительными заболеваниями кишечника (Национальные клинические рекомендации). Национальная ассоциация клинического питания, Москва, 2015

255. Федеральные клинические рекомендации по оказанию медицинской помощи детям с кистозным фиброзом (муковисцидозом) (Национальные клинические рекомендации). Союз педиатров России. 2015

256. Федеральные клинические рекомендации по оказанию медицинской помощи детям с целиакией (Национальные клинические рекомендации). Союз педиатров России. 2015

257. Всемирная Гастроэнтерологическая Организация, практические рекомендации, 2012

258. А. И. Парфенов Энтеропатия с нарушением мембранного пищеварения / Н. И. Белостоцкий, С. Р. Дбар, О. В. Ахмадуллина, С. В. Быкова, Е. А. Сабельникова. С. Г. Хомерики //Эффективная фармакотерапия. – 2018-№ 2- с. 20–26 Parfyonov A. I., Belostotsky N. I., Dbar S. R. et al. Enteropathy with Disorder of Membrane Digestion. Effective Pharmacotherapy. 2018;2(16):20–26

259. Л. Б. Лазебник Инновации в коррекции кишечных дисбиозов различного генеза /РМЖ- 2018- № 7 (1) – с. 2–6. Lazebnik L. B. Innovations in correction of intestinal dysbiosis of various origins. RMJ. Medical Review. 2018;7(I):2–6.

260. Suetsugu H et al. “Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa” J Lab Clin Med. 2000 Jul;136(1):50–7

261. Kleine A. et al. “Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats” Dig Dis Sci. 1993;38:1441–1449)

262. Ishihara K. et al. “Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa”, Arzneimitte lforschung 1992; 42(12), 1462–1466


Для цитирования:


Сарсенбаева А.С., Лазебник Л.Б. Диареи у взрослых. Клинические рекомендации. Проект. Экспериментальная и клиническая гастроэнтерология. 2020;(6):4-41. https://doi.org/10.31146/1682-8658-ecg-178-6-4-41

For citation:


Sarsenbaevа A.S., Lazebnik L.B. Diarrhea in adults. Clinical guidelines. Project. Experimental and Clinical Gastroenterology. 2020;(6):4-41. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-178-6-4-41

Просмотров: 165


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-8658 (Print)